Sionna Therapeutics
SION
47 hedge funds and large institutions have $434M invested in Sionna Therapeutics in 2025 Q1 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
94.04% more ownership
Funds ownership: 0% → 94.04% (+94%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$171M |
| 2 |
TGA
TPG GP A
Fort Worth,
Texas
|
+$109M |
| 3 |
O
OrbiMed
New York
|
+$60.5M |
| 4 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
+$60.4M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$48.2M |
Top Sellers
SION Hedge Fund Activity: Q1 2025 in Review
47 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Sionna Therapeutics (SION) for Q1 2025, worth a combined $434M.
Buyers outnumbered sellers: 47 funds opened new SION positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $171M.
- 47 institutional investors held Sionna Therapeutics (SION) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $434M of Sionna Therapeutics stock for Q1 2025.
- 47 funds opened new Sionna Therapeutics positions in Q1 2025 and 0 closed out, a net change of +47 holders.
- The largest Sionna Therapeutics buyer in Q1 2025 was RA Capital Management, an estimated $171M added.
Based on aggregated 13F filings for Q1 2025.